The antibiotic trial is seriously ground-breaking and what we do not know is what BOT supplied the FDA with to give us a glowing endorsement for the trial to proceed. You just cannot turn up on their doorstep and suggest you have a revolutionary product which appears to show no resistance to bacteria when applied topically and hope they believe you. Data must have been provided, and i am sure this was about one year ago. Why didnt they run with that only you ask?
Our CEO came on board last year but when and why? We were told he looked and looked and it was he who was instrumental in us being so heavily weighted in cash. Thirty six million he managed to get from the U.S. Why and what for you ask?
Biotechs are here for the patient and they are here for the patient so we have no choice than to be patient.
What is a replication of last years results worth in a much bigger phase 2 trial with exclusivity?
Bot Chart, page-3137
-
- There are more pages in this discussion • 12,206 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
34.5¢ |
Change
-0.005(1.43%) |
Mkt cap ! $627.0M | |||
| Open | High | Low | Value | Volume |
| 35.0¢ | 36.0¢ | 34.5¢ | $1.255M | 3.601M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 206282 | 34.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 35.0¢ | 316320 | 5 |
View Market Depth
| Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
| BOT (ASX) Chart |